Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590187593> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2590187593 endingPage "533" @default.
- W2590187593 startingPage "533" @default.
- W2590187593 abstract "533 Background: Phase III trials have tested biologic (bio) agents (bevacizumab [bev], anti-EGFR antibodies, ziv aflibercept [ziv]) plus chemotherapy (CT) vs. CT alone after failure of first-line therapy in patients given CT + bev first line. Several have shown improvements in progression-free and overall survival (OS) with the CT + bio approach, but it is not clear how these therapies are being used in the “real life” setting. Methods: Since 3/2013 PPrefs for this setting among 276 MOs were studied using a validated, proprietary, live, case-based market research tool. A core scenario and variations based on KRAS status and first-line therapy outcome were tested (S1, S2, S3, S4). PPref data acquired using blinded audience response technology. All sources of research support were blinded. Core scenario: 49 yr old female with cecal mass, liver/lung metastases, confirmed wt KRAS for S1-3, given FFB first line. S1: FFB x 16 wks → excellent PR → 5FU bev X 16 wks → progressive disease [PD]; S2: FFB x 16 wks → excellent PR → bev alone x 16 wks → PD; S3: FFB → stable disease [SD] x 5 months as best response [BR] → PD; 4) Here changed to mutKRAS; FFB x 8 wks → PD as BR. Results: Findings shown below (Table). Conclusions: In scenarios with wt KRAS, first-line response to FFB, a majority plan bev again second line. If BR to FFB is SD in WT KRAS, anti-EGFR antibody-based therapy is used more often. In S 1-3, ziv is the PPref of 7 - 14% of MOs studied. With mutKRAS and PD as BR to FFB, use of an antiangiogenic + second-line CT is preferred by > 80%, nearly equally split between bev and ziv. Recent phase III trial data showing OS benefits are reflected in current MOs first failure PPrefs. [Table: see text]" @default.
- W2590187593 created "2017-03-03" @default.
- W2590187593 creator A5000749891 @default.
- W2590187593 creator A5028472820 @default.
- W2590187593 creator A5028935523 @default.
- W2590187593 creator A5043909412 @default.
- W2590187593 creator A5067038031 @default.
- W2590187593 creator A5067982924 @default.
- W2590187593 creator A5075108469 @default.
- W2590187593 date "2014-01-20" @default.
- W2590187593 modified "2023-09-27" @default.
- W2590187593 title "Prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) for choice of therapy after failure of first-line FOLFOX plus bevacizumab (FFB) in patients with metastatic colorectal cancer (MCC)." @default.
- W2590187593 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.533" @default.
- W2590187593 hasPublicationYear "2014" @default.
- W2590187593 type Work @default.
- W2590187593 sameAs 2590187593 @default.
- W2590187593 citedByCount "0" @default.
- W2590187593 crossrefType "journal-article" @default.
- W2590187593 hasAuthorship W2590187593A5000749891 @default.
- W2590187593 hasAuthorship W2590187593A5028472820 @default.
- W2590187593 hasAuthorship W2590187593A5028935523 @default.
- W2590187593 hasAuthorship W2590187593A5043909412 @default.
- W2590187593 hasAuthorship W2590187593A5067038031 @default.
- W2590187593 hasAuthorship W2590187593A5067982924 @default.
- W2590187593 hasAuthorship W2590187593A5075108469 @default.
- W2590187593 hasConcept C121608353 @default.
- W2590187593 hasConcept C126322002 @default.
- W2590187593 hasConcept C141071460 @default.
- W2590187593 hasConcept C143998085 @default.
- W2590187593 hasConcept C2776694085 @default.
- W2590187593 hasConcept C2776705615 @default.
- W2590187593 hasConcept C2777802072 @default.
- W2590187593 hasConcept C2778260052 @default.
- W2590187593 hasConcept C2778749236 @default.
- W2590187593 hasConcept C2778822529 @default.
- W2590187593 hasConcept C2779984678 @default.
- W2590187593 hasConcept C2779998722 @default.
- W2590187593 hasConcept C2780259306 @default.
- W2590187593 hasConcept C2780962732 @default.
- W2590187593 hasConcept C2781187634 @default.
- W2590187593 hasConcept C526805850 @default.
- W2590187593 hasConcept C71924100 @default.
- W2590187593 hasConceptScore W2590187593C121608353 @default.
- W2590187593 hasConceptScore W2590187593C126322002 @default.
- W2590187593 hasConceptScore W2590187593C141071460 @default.
- W2590187593 hasConceptScore W2590187593C143998085 @default.
- W2590187593 hasConceptScore W2590187593C2776694085 @default.
- W2590187593 hasConceptScore W2590187593C2776705615 @default.
- W2590187593 hasConceptScore W2590187593C2777802072 @default.
- W2590187593 hasConceptScore W2590187593C2778260052 @default.
- W2590187593 hasConceptScore W2590187593C2778749236 @default.
- W2590187593 hasConceptScore W2590187593C2778822529 @default.
- W2590187593 hasConceptScore W2590187593C2779984678 @default.
- W2590187593 hasConceptScore W2590187593C2779998722 @default.
- W2590187593 hasConceptScore W2590187593C2780259306 @default.
- W2590187593 hasConceptScore W2590187593C2780962732 @default.
- W2590187593 hasConceptScore W2590187593C2781187634 @default.
- W2590187593 hasConceptScore W2590187593C526805850 @default.
- W2590187593 hasConceptScore W2590187593C71924100 @default.
- W2590187593 hasIssue "3_suppl" @default.
- W2590187593 hasLocation W25901875931 @default.
- W2590187593 hasOpenAccess W2590187593 @default.
- W2590187593 hasPrimaryLocation W25901875931 @default.
- W2590187593 hasRelatedWork W1991332977 @default.
- W2590187593 hasRelatedWork W2071471252 @default.
- W2590187593 hasRelatedWork W2134986421 @default.
- W2590187593 hasRelatedWork W2159303174 @default.
- W2590187593 hasRelatedWork W2410307605 @default.
- W2590187593 hasRelatedWork W2495009374 @default.
- W2590187593 hasRelatedWork W2802627520 @default.
- W2590187593 hasRelatedWork W2892376819 @default.
- W2590187593 hasRelatedWork W2939662662 @default.
- W2590187593 hasRelatedWork W67135169 @default.
- W2590187593 hasVolume "32" @default.
- W2590187593 isParatext "false" @default.
- W2590187593 isRetracted "false" @default.
- W2590187593 magId "2590187593" @default.
- W2590187593 workType "article" @default.